Finance

Lists
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
USD 9,51
-4,33%
(-0,43) 1D
USD 9,00
-5,36% (-0,51)
Pre-market
Closed: 29 Jul., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
USD 10,00
High
USD 10,31
Low
USD 9,43
Mkt. cap
151,60 m
Avg. vol.
536,49 k
Volume
3,13 k
52-wk high
USD 69,96
52-wk low
USD 9,43
EPS
-USD 14,34
Beta
1,64
Shares outstanding
15,94 m
No. of employees
142
Open
USD 10,00
High
USD 10,31
Low
USD 9,43
Mkt. cap
151,60 m
Avg. vol.
536,49 k
Volume
3,13 k
52-wk high
USD 69,96
52-wk low
USD 9,43
EPS
-USD 14,34
Beta
1,64
Shares outstanding
15,94 m
No. of employees
142
News stories
From sources across the web
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersBerkeley Heights, New Jersey, Verenigde State van Amerika
Sector-
Websitetonixpharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current USD 9,51
USD 65,00 (+583,49%)
Average
USD 37,67 (+296,11%)
Lowest
USD 22,00 (+131,34%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Reiterated
USD 65,00
+583,5%
07/13/2026
Stacy Ku
TD Cowen
Buy
Maintained
USD 22,00
+131,3%
06/29/2026
Tiago Fauth
Raymond James
Buy
Initiated
USD 26,00
+173,4%
06/25/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
USD 37,00
+289,1%
03/16/2026
Last report
11 Mei 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-USD 2,93 / -USD 2,98
+1,68%beat
Revenue / Est. (USD)
6,88 m / 7,00 m
-1,74%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
2,00 m
3,29 m
5,39 m
6,88 m
Cost of goods sold
3,27 m
1,37 m
1,06 m
1,58 m
Cost of revenue
3,27 m
1,37 m
1,06 m
1,58 m
Research and development expenses
10,82 m
9,29 m
16,94 m
18,21 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,20 m
25,70 m
35,68 m
28,62 m
Operating expense
27,02 m
34,99 m
52,62 m
46,84 m
Total operating expenses
30,29 m
36,36 m
53,68 m
48,42 m
Operating income
-28,30 m
-33,07 m
-48,29 m
-41,54 m
Other non operating income
-919,00 k
-174,00 k
32,00 k
-3,00 k
EBT including unusual items
-28,27 m
-32,01 m
-46,91 m
-40,19 m
EBT excluding unusual items
-28,27 m
-32,01 m
-46,91 m
-40,19 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-28,27 m
-32,01 m
-46,91 m
-40,19 m
Net profit margin
-1 415,02%
-972,95%
-870,32%
-584,38%
Earnings per share
-4,00
-3,70
-3,98
-2,93
Interest and investment income
943,00 k
1,23 m
1,34 m
1,35 m
Interest expense
-
-
-
-
Net interest expenses
943,00 k
1,23 m
1,34 m
1,35 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-27,81 m
-32,61 m
-47,80 m
-40,98 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer